Wall Street worshiped large pharmaceutical companies for much of the past two decades, and for good reason: The big pharmas had it all rock-solid balance sheets, strong earnings and a seemingly endless pipeline of...
The recent bear market was one of the worst in history, but investors in the Calamos Market Neutral Fund, a mutual fund, hardly noticed. With annual total returns averaging a solid, if unspectacular, 8.4 percent from...
